Journal: BMJ Open Ophthalmology

Article Title: Functional benefits of a chorioretinal anastomosis at 2 years in eyes with a central retinal vein occlusion treated with ranibizumab compared with ranibizumab monotherapy

doi: 10.1136/bmjophth-2021-000728

Figure Lengend Snippet: Predicted BCVA across time and treatment groups. These are control or ranibizumab monotherapy, non-functioning L-CRA and functioning L-CRA. Timepoint comparisons (months 7, 13 and 24) were made against the month 1 data, which was when all groups commenced mandatory monthly ranibizumab for 6 months. Vertical bars are ±1 SEM. BCVA, best corrected visual acuity; ETDRS, Early Treatment Diabetic Retinopathy Study; L-CRA, laser-induced chorioretinal anastomosis.

Article Snippet: Between baseline and month 1 (ranibizumab commenced), there was a mean (95% CI) CST reduction for the functioning L-CRA group of 208 µm (−314 to –102) compared with the control group (p=<0.0001), presumably due to the effects of the developing L-CRA.

Techniques:

Journal: BMJ Open Ophthalmology

Article Title: Functional benefits of a chorioretinal anastomosis at 2 years in eyes with a central retinal vein occlusion treated with ranibizumab compared with ranibizumab monotherapy

doi: 10.1136/bmjophth-2021-000728

Figure Lengend Snippet: Predicted BCVA across time and treatment groups. These are control or ranibizumab monotherapy, non-functioning L-CRA and functioning L-CRA. Timepoint comparisons (months 7, 13 and 24) were made against the month 1 data, which was when all groups commenced mandatory monthly ranibizumab for 6 months. Vertical bars are ±1 SEM. BCVA, best corrected visual acuity; ETDRS, Early Treatment Diabetic Retinopathy Study; L-CRA, laser-induced chorioretinal anastomosis.

Article Snippet: For the remaining duration of the study (months 7–24, maintenance phase), participants continued to be evaluated monthly and received intravitreal ranibizumab if they met the following criteria: (1) >50 µm increase in CST on spectral domain optical coherence tomography (SD-OCT) compared with the lowest previous measurement; (2) new or persistent cystic retinal changes, subretinal fluid or persistent diffuse oedema ≥270 µm in CST; and (3) loss of five or more letters on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart from the previous best measurement in conjunction with any increase in CST.

Techniques: